News
NEJM Publishes Phase 3 MARIPOSA Trial: Amivantamab plus Lazertinib Sets New Standard in EGFR-Mutant NSCLC
Through global collaboration with multinational pharmaceutical companies, a domestically developed anticancer drug has once again been published in the world-renowned New England Journal of Medicine
Yuhan Signs HIV Drug API Supply Contract with Gilead
On the 20th, Yuhan Corporation announced that it has signed a contract with multinational pharmaceutical company Gilead Sciences to supply the active pharmaceutical ingredient (API)
Lazertinib + SBRT Shows Promising Results in EGFR-Mutant Oligometastatic NSCLC
A phase 2 clinical trial led by Korean investigators demonstrated that combining the third-generation EGFR inhibitor lazertinib (Leclaza® in Korea, Lazcluzy® internationally) with stereotactic body
Amivantamab + Lazertinib Shows Significant Benefits in EGFR-Mutant NSCLC
Johnson & Johnson’s Innovative Medicine (formerly Janssen) reported that the combination of amivantamab (Rybrevant®) and lazertinib (Leclaza® in Korea, Lazcluze® internationally), developed by Yuhan Corporation,
Hiring – Business Development Manager
Business Development Manager Yuhan USA Corporation Work locations: Cambridge, MA Employee type: Full-time Contact Information: info@yuhan-usa.com Yuhan USA Corporation was established in January 2018 as a
Janssen Gains China Approval for Lazertinib + Amivantamab Combo in EGFR-Mutant NSCLC
Date: 08/01/25 Yuhan Corporation’s novel EGFR-targeting non-small cell lung cancer (NSCLC) therapy Leclaza (lazertinib) has received official marketing approval in China, further solidifying its global